Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 3;14:2003–2013. doi: 10.2147/COPD.S210897

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Tavakoli et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Trends in the proportion of patients filling at least one prescription (left) and average dose-adjusted number of canisters (right*) for major COPD inhaled therapies, from 1997 to 2015.

Notes: *Numbers in brackets on the right panel legend give the average change between consecutive years. The baseline year for the trend is the first year of the medication’s presence in BC: 1997 for ICS, SABA, SAMA, LABA, and SAMA/SABA, 1999 for ICS/LABA, 2002 for LAMA, 2013 for LAMA/LABA (which is not presented in the figure due to the short duration).

Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting beta-2 adrenoceptor agonists; LAMA, and long-acting muscarinic agents; SABA, short-acting beta-agonists; SAMA, short-acting muscarinic agents.